Advertisement

Topics

Esperion Therapeutics Inc. Company Profile

05:52 EDT 18th June 2018 | BioPortfolio

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for the treatment of patients with hypercholesterolemia and other cardiometabolic risk markers. ETC-1002, Esperion's lead product candidate, is a unique, first-in-class, orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with the currently available LDL-cholesterol lowering therapies. ETC-1002 is being developed primarily for patients intolerant of statins with elevated levels of LDL-cholesterol. Phase 2b clinical trials for ETC-1002 are currently underway and build upon a successful and comprehensive Phase 1 and Phase 2 program. For more information, please visit www.esperion.com and follow us on Twitter at https://twitter.com/EsperionInc.


News Articles [835 Associated News Articles listed on BioPortfolio]

Pomerantz LLP: SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Esperion Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - ESPR

NEW YORK, NY / ACCESSWIRE / May 26, 2018 / Pomerantz LLP announces that a class action lawsuit has been filed against Esperion Therapeutics, Inc. ("Esperion" or the "Company") (NASDAQ: ESPR) and ce...

Kaskela Law LLC: DEADLINE NOTICE: Shareholder Class Action Lawsuit Filed Against Esperion Therapeutics, Inc. - ESPR

RADNOR, PA/ ACCESSWIRE / May 26, 2018 / Kaskela Law LLC announces that a shareholder class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ: ESPR) ("Esperion" or the "Compa...

Esperion Therapeutics (ESPR) Holdings Lifted by Teachers Advisors LLC

Teachers Advisors LLC grew its position in Esperion Therapeutics by 3.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund ow...

Esperion's cholesterol drug succeeds in late-stage study

REUTERS: Esperion Therapeutics Inc said on Wednesday a late-stage trial of its experimental oral drug met the main goal of reducing cholesterol by 28 percent in patients suffering from, or at a high r...

Pawar Law Group: Esperion Therapeutics, Inc. Reminder: Pawar Law Reminds of Important July 6, 2018 Lead Plaintiff Deadline in Class Action- ESPR

NEW YORK, NY / ACCESSWIRE / June 5, 2018 / Pawar Law Group reminds shareholders who purchased shares of Esperion Therapeutics, Inc. (NASDAQ: ESPR) from February 22, 2017 through May 1, 2018, both d...

Esperion's drug clears study as add-on cholesterol treatment

(Reuters) - Esperion Therapeutics Inc said on Tuesday its experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients, who were already on another treatment to lower the...

The Klein Law Firm Notifies Investors of a Class Action Commenced on Behalf of Esperion Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of July 6, 2018 (ESPR)

NEW YORK, NY / ACCESSWIRE / June 5, 2018 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Esperion Therapeutics, Inc. (NASDAQ: ESPR) who purc...

EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Esperion Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2018 - ESPR

NEW YORK, NY / ACCESSWIRE / June 4, 2018 / The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Esperion T...

PubMed Articles [413 Associated PubMed Articles listed on BioPortfolio]

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Introduction to Volume 1 of JOPT Special Issue.

Clinical Trials [144 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1237 Associated Companies listed on BioPortfolio]

Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., located in Plymouth, Michigan, discovers and develops novel therapies for the treatment of cardiovascular and metabolic diseases. The company is funded by top tier venture...

Esperion Therapeutics Inc.

Esperion Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, LDL-cholesterol lowering therapies for...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

Vaxiion Therapeutics, Inc.

Vaxiion is dedicated to the design and development of intelligent drug-delivery technologies with special emphasis on targeted oncology therapeutics. Vaxiion Therapeutics was spun...

More Information about "Esperion Therapeutics Inc." on BioPortfolio

We have published hundreds of Esperion Therapeutics Inc. news stories on BioPortfolio along with dozens of Esperion Therapeutics Inc. Clinical Trials and PubMed Articles about Esperion Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Esperion Therapeutics Inc. Companies in our database. You can also find out about relevant Esperion Therapeutics Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record